Loading clinical trials...
Loading clinical trials...
Exploratory Clinical Study of JAK1 Inhibitor Golidocitnib in the Treatment of Relapsed/Refractory Indolent T/NK-Cell Lymphomas：An Open, Prospective, Exploratory Clinical Trial
Conditions
Interventions
JAK1 Inhibitor
Locations
2
China
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, Tianjin Municipality, China
Institute of Hematology & Blood Diseases Hospital
Tianjin, China
Start Date
December 25, 2024
Primary Completion Date
November 15, 2026
Completion Date
November 15, 2028
Last Updated
November 18, 2025
NCT06561048
NCT07356245
NCT02863692
NCT06534060
NCT06947967
NCT06530550
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions